Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer
Shuiqing Xu, Jinzhen Guo, Ziyi Zhao, Yan Zhai, Yingying Liu, Hua Li · 2026
Read Clinical Value of an LDH–CA125–NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer by Shuiqing Xu, Jinzhen Guo, Ziyi Zhao, Yan Zhai, Yingying Liu, Hua Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13605179.txt.
Description
Shuiqing Xu and co-authors test a trio of routine blood markers for ovarian cancer diagnosis and drug resistance, in work from twenty twenty-six. Epithelial ovarian cancer lacks cheap early flags for care teams. Three blood values are cheap and already drawn in most workups. Matched patients with benign growths serve as the comparison group. Continuous values feed diagnosis models, while a triple-high flag is also tested.
The three-marker model separates cancer from benign cases well overall. It performs far better in advanced stage than in early stage disease. Adding the third marker does not lift the pair model significantly. Triple-high status links strongly to platinum drug resistance, though. It also links to shorter time before disease returns. In advanced disease it links to shorter survival as well. Outside validation is still needed before clinic use.
Catalog record
| CREATOR | Shuiqing Xu, Jinzhen Guo, Ziyi Zhao, Yan Zhai, Yingying Liu, Hua Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |